This has moved beyond theory for some lung cancer patients as, in Cuba, a vaccine that raises antibodies against EGF (CimaVax‐EGF) is approved for use as a maintenance therapy in advanced NSCLC [15]. This evidence concerns the gene EGF and lung cancer.